ArticleACS omega2021
Development of a Rapid
Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Engineered Melittin Delivers a Drug-Loaded 'Chemo-Sting' to Overcome Efflux-Mediated Multidrug Resistance in Cancer Cells.Pharmaceutics · 2026Article
- Dehydrative formation and biological evaluation of allylic sulfonamides from allylic alcohols using recyclable silica-supported acid catalysts.RSC advances · 2026Article
- Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond.npj biomedical innovations · 2026Article
- VUScope: a mathematical model for evaluating image-based drug response measurements and predicting long-term incubation outcomes.Bioinformatics (Oxford, England) · 2026Article
- The Essential Oil Component Terpinyl Acetate Alters Honey Bee Energy Levels and Foraging Behavior.Insects · 2025Article
- Tracking Small Extracellular Vesicles Using a Minimally Invasive PicoGreen Labeling Strategy.ACS applied bio materials · 2024Article
- The Effect of 4-(Dimethylamino)phenyl-5-oxopyrrolidines on Breast and Pancreatic Cancer Cell Colony Formation, Migration, and Growth of Tumor Spheroids.International journal of molecular sciences · 2024Article
- Chloroquine-Based Mitochondrial ATP Inhibitors.Molecules (Basel, Switzerland) · 2023Article
- The Effect of 1,2,4-Triazole-3-thiol Derivatives Bearing Hydrazone Moiety on Cancer Cell Migration and Growth of Melanoma, Breast, and Pancreatic Cancer Spheroids.Pharmaceuticals (Basel, Switzerland) · 2022Article
- NovelInternational journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional long exposure (24-72 h) cell viability assays for identification of potential drug compounds can fail to identify compounds that are: (a) biologically active but not toxic and (b) inactive without the addition of a synergistic additive. Herein, we report the development of a rapid (1-2 h) compound screening technique using a commercially available cell viability kit (CellTiter-Glo) that has led to the detection of compounds that were not identified as active agents using traditional cytotoxicity screening methods. These compounds, in combination with metabolic inhibitor 2-deoxyglucose, display selectivity toward a pancreatic cancer cell line. An evaluation of 11 mammalian cell lines against 30 novel compounds and two metabolic inhibitors is reported. The inclusion of metabolic inhibitors during an initial screening process, and not simply during mechanistic investigations of a previously identified hit compound, provides a rapid and sensitive tool for identifying drug candidates potentially overlooked by other methods.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.